StreetInsider.com News Articles

Context Therapeutics (CNTX) PT Lowered to $4 at Maxim Group

Tue, 16 Jun 2026 09:55:15 -0400

Maxim Group analyst Jason McCarthy lowered the price target on Context Therapeutics (NASDAQ: CNTX) to $4.00 (from $8.00) while maintaining a Buy rating.

Form 8-K Context Therapeutics For: Jun 15

Mon, 15 Jun 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260615/26645191.html

Form 8-K Context Therapeutics For: Jun 15

Mon, 15 Jun 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260615/26645191.html

Context Therapeutics reports interim phase 1 trial results for CTIM-76

Mon, 15 Jun 2026 06:30:19 -0400

Context Therapeutics Inc. (NASDAQ: CNTX) announced interim results from its ongoing Phase 1 clinical trial of CTIM-76, a bispecific antibody targeting platinum-resistant ovarian cancer. The data covers 21 patients treated with doses ranging from 22.5µg to 560µg administered weekly, as of a May 29, 2026 data cutoff.

In patients with platinum-resistant ovarian cancer who received active doses of 140µg to 280µg, the company reported a 29% confirmed overall response rate based on RECIST v1.1 criteria. Seven patients were evaluable for efficacy at these dose levels, with two achieving confirmed partial responses. The disease control rate reached 57% among evaluable patients.

The trial

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Mon, 15 Jun 2026 06:30:00 -0400

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy

Cytokine Release Syndrome (“CRS”) in PROC limited to Grade 1 in 11% of patients

Pharmacokinetic (“PK”) profile supports exploration of Q3W dosing in 2H 2026

CTIM-76 has been granted FDA Fast Track Designation in PROC

Company to host conference call on Monday, June 15 at 8:00 a.m. ET

PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”)

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Mon, 15 Jun 2026 06:30:00 -0400

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy

Cytokine Release Syndrome (“CRS”) in PROC limited to Grade 1 in 11% of patients

Pharmacokinetic (“PK”) profile supports exploration of Q3W dosing in 2H 2026

CTIM-76 has been granted FDA Fast Track Designation in PROC

Company to host conference call on Monday, June 15 at 8:00 a.m. ET

PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”)

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Mon, 15 Jun 2026 06:30:00 -0400

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy

Cytokine Release Syndrome (“CRS”) in PROC limited to Grade 1 in 11% of patients

Pharmacokinetic (“PK”) profile supports exploration of Q3W dosing in 2H 2026

CTIM-76 has been granted FDA Fast Track Designation in PROC

Company to host conference call on Monday, June 15 at 8:00 a.m. ET

PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”)

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Mon, 15 Jun 2026 06:30:00 -0400

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy

Cytokine Release Syndrome (“CRS”) in PROC limited to Grade 1 in 11% of patients

Pharmacokinetic (“PK”) profile supports exploration of Q3W dosing in 2H 2026

CTIM-76 has been granted FDA Fast Track Designation in PROC

Company to host conference call on Monday, June 15 at 8:00 a.m. ET

PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”)

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 09 Jun 2026 16:10:00 -0400

PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 09 Jun 2026 16:10:00 -0400

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 09 Jun 2026 16:10:00 -0400

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 09 Jun 2026 16:10:00 -0400

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 07:30:00 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its presentation at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 7:35 a.m. ET.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at https://ir.contexttherapeutics.com. Replays will be available on the website for 90 days.

For additional information or to request a meeting with members of Context’s

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 07:30:00 -0400

For additional information or to request a meeting with members of Context’s

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 07:30:00 -0400

For additional information or to request a meeting with members of Context’s

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 07:30:00 -0400

For additional information or to request a meeting with members of Context’s

Form 8-K Context Therapeutics For: May 14

Mon, 18 May 2026 06:47:00 -0400

si-local-file:///var/storage/secattach/20260518/26509879.html

Form 8-K Context Therapeutics For: May 14

Mon, 18 May 2026 06:47:00 -0400

si-local-file:///var/storage/secattach/20260518/26509879.html

Context Therapeutics amends BioAtla license deal for CT-202 drug

Mon, 18 May 2026 06:45:12 -0400

Context Therapeutics Inc. (NASDAQ: CNTX) amended its exclusive license agreement with BioAtla Inc. (NASDAQ: BCAB) for CT-202, eliminating future milestone and royalty payments in exchange for $6.5 million in total payments.

The biopharmaceutical company will pay $4.5 million upfront and an additional $2.0 million by August 1, 2026, according to a statement based on the press release. The amendment modifies the original license agreement dated September 23, 2024.

CT-202 is a Nectin-4 x CD3 T cell engager bispecific antibody targeting Nectin-4, a protein overexpressed in bladder, colorectal, lung and breast tumors. The company expects to initiate a Phase 1 clinical trial for

Context Therapeutics amends BioAtla license deal for CT-202 drug

Mon, 18 May 2026 06:45:12 -0400

Context Therapeutics amends BioAtla license deal for CT-202 drug

Mon, 18 May 2026 06:45:12 -0400

Context Therapeutics amends BioAtla license deal for CT-202 drug

Mon, 18 May 2026 06:45:12 -0400

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Mon, 18 May 2026 06:45:00 -0400

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license

Phase 1 initiation for CT-202 trial expected in third quarter of 2026

PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Mon, 18 May 2026 06:45:00 -0400

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license

Phase 1 initiation for CT-202 trial expected in third quarter of 2026

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Mon, 18 May 2026 06:45:00 -0400

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license

Phase 1 initiation for CT-202 trial expected in third quarter of 2026